Consider The Advantages...

Human Hepatocyte CYP450 Induction

Induction of human CYP450 enzymes causes drug-drug interactions that you need to know about.

In Vitro Technologies provides the solution with a human hepatocyte CYP450 induction testing service. Just send us your drug samples and we'll provide the answer.

In Vitro Technologies is the leading U.S. company dedicated exclusively to providing state-of-the-art in vitro testing services for studying human drug metabolism, drug-drug interactions, absorption, and the toxic effects of chemicals on the liver, kidney, heart, skin and eye.
INSTRUCTIONS TO AUTHORS

Submission of manuscripts. DRUG METABOLISM AND DISPOSITION will consider for publication manuscripts describing the results of original research that contribute significant and novel information on xenobiotic metabolism and disposition. The term xenobiotic includes therapeutic agents as well as environmental chemicals, and research may involve the use of in vivo or in vitro approaches, including cultured cells and heterologous expression systems. Manuscripts describing the results of pharmacokinetic/pharmacodynamic research are invited. Manuscripts that examine mechanistic aspects of xenobiotic metabolism as well as those examining mechanisms that affect xenobiotic metabolism or disposition, including drug-metabolizing enzyme expression, regulation of drug-metabolizing enzyme gene expression, and genetic polymorphism, are encouraged. Manuscripts concerned with genetic, nutritional, or hormonal factors that influence the biological fate of chemicals are also of interest, as are those that address the toxicologic consequences of xenobiotic metabolism.

Four copies of each manuscript should be sent to Dr. Raymond F. Novak, Editor, DRUG METABOLISM AND DISPOSITION, The Institute of Chemical Toxicology, Wayne State University, 2727 Second Avenue, Room 4000, Detroit, MI 48201-2654. Telephone: (313) 961-4943. Fax: (313) 961-0026 or 577-0082. Submission of a manuscript implies that the material contained therein has not previously been published except as an abstract for a scientific meeting, and that it is not being submitted elsewhere.

All manuscripts received in the editorial office must be accompanied either by a check for $40.00 (in U.S. funds payable to ASPET) or by a validated purchase order form from the author’s institution. The review process for submitted manuscripts will be delayed until the manuscript handling fee or purchase order form is received in the Editor’s office. If the submission of the manuscript handling fee entails a personal financial hardship to the author(s), the manuscript handling fee will be waived. In that event, the authors should submit a request for waiver of the fee at the time the manuscript is submitted.

If and when manuscripts are accepted for publication, it will be necessary for the American Society for Pharmacology and Experimental Therapeutics, Inc., to receive in writing assignment of copyright from all authors of each manuscript. The exception would be when the work was done by employees of U.S. federal government. The forms for this assignment will be mailed from the Editorial Office. If the original copyright belongs to an agency other than the authors, the assignment form must be signed by the proper authority, with an attached document indicating the nature of the copyright agreement.

After Acceptance: When an article has been accepted for publication, the final manuscript may be sent to the Editorial Office on diskette. A hard copy must accompany the diskette. This will expedite the publication process for Williams & Wilkins.

Authors are encouraged to submit electronic diskettes of the final version of their manuscripts along with the typed REVISED manuscript. Diskettes produced on IBM or IBM-compatible computers are preferred, but those produced on most Apple/Macintosh or Wang computers can also be converted. The following word processing programs are preferred: XyWrite III Plus, Word Perfect 4.2, 5.0, or 5.1 (IBM or Macintosh), Microsoft Word (IBM or Macintosh), Wang OIS (WPS), and Wordstar (IBM). Other word processing systems that we can convert are CPT 8000, MacWrite 2.2 or 4.5, Display Write 3 or 4, Multimate, PC Write, Volkswriter, and Write Now. Authors preparing diskettes on Macintosh computers should not use the Fast Save option. Files in ASCII can also be used but are not preferred. Identify the diskette by providing journal name, manuscript number, senior author’s name, manuscript title, name of computer file, type of hardware, operating system and version number, and software program and version number.

The journal does not assume responsibility for errors in conversion of customized software, newly released software, and special characters. Mathematics and tabular material will be processed in the traditional manner.

Form and style of manuscript. Manuscripts, in English language only, should be typewritten double-spaced with ample margins, on one side of 8.5 × 11-inch pages. The original typescript and three copies, which may be Xerox or other good reproductions, or legible carbon copies, should be sent. All pages should be numbered in sequence, starting with the title page.

A. Full-length papers. Full papers should be arranged as follows:

1. Title page, containing the title of the paper, names of all authors, and the institution(s) where the work was done. The title should have no footnote numbers (see Footnotes below). The title should briefly yet explicitly indicate the contents of the paper. Names of chemicals or chemical classes studied, species used, etc., should be included in the title.

2. Running title not exceeding 50 total characters and spaces. Please note the Running Title will be used for the front page summary. These should not use commercially designated drug numbers or other unaccepted abbreviations (e.g., change "Biotransformation of XYZ-89843" to "Biotransformation of a Pyrrolopyrimidine Analog"). The name and address of the person to whom editorial correspondence and galley proofs should be sent should appear at the bottom of this page.

3. Abstract of not more than 250 words.

4. Introduction. A brief summary of the pertinent literature and a statement of the aims of the work.

5. Materials and Methods. Species, strains, sexes, and ages or sizes of animals, with Latin names where required for distinction, should be given. Sources and purities of chemicals other than common reagents should be indicated. Equipment used and conditions of use should be specified. When published methods are used, a bibliographic reference is sufficient; minor modifications should be described. When a method has been extensively modified, the entire new procedure should be described. Authors should attempt to describe their work in all cases so that their peers would be able to repeat the experiments. Where conditions for similar experiments vary throughout the work, these may be indicated in legends to figures and tables. Properties and proof of structure must be given for reference compounds used for metabolite identification.

6. Results. These should be presented as much as possible in graphic and tabular form. When, however, a table would include
only two or three values, it may be preferable to present the data in sentence form in the text. Authors should avoid using several tables describing very similar experiments; these should be combined wherever possible, unless this would result in overcomplicated, unwieldy tables. The same data should normally not be repeated in tables and figures. The text should be used to describe and summarize the data and to draw primary conclusions from them, but not to repeat the numerical data. No extended discussion of the results should be included in this section.

7. Discussion. The major conclusions to be drawn from the work should be assembled here, and these should be discussed with respect to the existing body of knowledge in the immediate area. Graphic schema should be used wherever possible to clarify the conclusions. Speculation should be clearly identified as such, and should be germane to the data presented. Questions raised by the work, or those inherent in the experiments, should be discussed.

Although it is normally preferable to separate the Results and Discussion sections, these sections, e.g., when an extended discussion of some of the experiments is required for an understanding of subsequent experiments, may have to be combined occasionally.

8. Acknowledgments of technical assistance, gifts of materials, and other aid. Financial support should not be mentioned here, but rather in an unnumbered footnote to the title (see Footnotes, below).

9. References, numbered in order of citation in the text. Examples of style of references follow:

Papers that have actually been accepted for publication may be cited among the references; give authors, journal name, and the words “in press.” Work not published or accepted, or personal communications, should be cited by footnote. Where knowledge of unpublished work is crucial to evaluation of a paper, duplicate copies of the pertinent data should be submitted with the manuscript for examination by the referees.

Authors are urged to exercise the utmost care that references are accurate. As a rule, references should not be included that have not been examined personally by the author. When, because of its rarity of language, the primary reference could not be examined, the secondary source should be indicated as well, as follows:

References should be cited in the text by numbers within parentheses. Abbreviations of journal names should be those given in Index Medicus.

10. Footnotes, presented in the following order:
   (a) Unnumbered footnote giving source of financial support, thesis information, citation of abstracts of meetings where this work was presented, etc., and, in a separate paragraph, the name and full address (with street address or P.O. box where applicable, and zip code number) of person to receive reprint requests.
   (b) Numbered footnotes, starting with those (if any) to authors’ names. Number footnotes in sequence throughout the text, using superscript numbers.

11. Tables, each on a separate page. Tables are to be numbered with arabic numbers. The title should be in italics (or underlined) with only the first word and proper names capitalized. General statements about the table should follow the title in paragraph form. Footnotes to the table should be indicated by italicized lower case superscript letters, starting with a for each table. Footnotes should be typed immediately below each table.

12. Legends for figures. Figures should be numbered with arabic numbers, followed by the title in italics (or underlined), with only the first word and proper nouns capitalized. The remainder of the explanatory material should be in paragraph form below the title.

13. Index terms. A list of index terms which may be used in constructing the annual index should constitute the last typed page of the manuscript.

14. Figures should be submitted with the original typescript as unmounted glossy photographic prints no larger than 8 × 10 inches (20 × 25 cm). Xerox or other good reproductions of line prints may accompany the other two copies of the manuscript; in the case of half-tone material, three photographic prints should be sent. Letters, numbers, and symbols must be large enough to be readily legible after reduction to single-column size; these should be at least 1.5 mm high after reduction. The style of figures should be uniform throughout the paper. For halftone figures, any part of the image unnecessary for clarity and understanding should be deleted from the final printed figure. The part of the image to be deleted should be marked on a photocopy and attached to the original for the printer to follow. Figures should be simple and uncluttered, so that they are readily understandable after reduction in size. Thus, in line graphs with multiple lines, it is usually preferable to use different symbols for the experimental points for different lines, with the explanation of symbols in the legend, rather than to attempt to label individual lines. Abscissa and ordinate should be clearly labeled with scale, name, and dimensions of quantities expressed.

B. Short Communications. Short Communications should be divided into sections the same way as full papers, but the Results and Discussion sections may be combined at the author’s discretion. Short Communications are subject to the same review process as full papers. The total length of a short communication may not exceed 10 typewritten pages, double-spaced with each figure counting as one page. Structural formulae of parent compounds and metabolites should be given; where possible, these should be general formulae with variable groups identified in a legend. Title, author’s names and affiliations, footnotes, captions, legends, references, and index terms should follow the forms outlined above for full papers.

C. Reviews. Contemporary reviews on topics of interest covering the more recent aspects of a subject in the area of interest will be published. These may be critical reviews that present the author’s view of the current state of the subject or prospective articles intended to stimulate discussion and research. Manuscripts submitted under this category should be accompanied by a transmittal letter that highlights the significance of the work and includes a list of at least four scientists who could serve as appropriate reviewers.

D. Letters. Letters to the editor are invited, in which relevant work described in this or other journals is discussed, interesting points raised as suggestions for further work, or new interpretations of existing data made. Where appropriate, authors of papers to which reference is made will be invited to reply. Letters presenting new data will not normally be accepted.

E. Accelerated Communications. Accelerated Communications are intended for the rapid dissemination of novel experimental observations of a timely, unusual, or special significance.
Accelerated Communications should contain novel or unusual findings that are documented clearly and contribute conceptually to the advancement of the field. Manuscripts will be reviewed using the same criteria applied to full papers, but reviews will be expedited. Manuscripts submitted under this category should be accompanied by a transmittal letter that highlights the significance of the work and includes a list of at least four scientists who could serve as appropriate reviewers. Accelerated Communications are not intended for publication of preliminary results.

Accelerated Communications will be reviewed as rapidly as possible with an objective of reaching a decision within 3 weeks after receipt. It is anticipated that accelerated communications will be published essentially in the form submitted. Manuscripts requiring minor (but significant) revisions will be returned for appropriate changes. Manuscripts that require major revision or that fail to meet the Accelerated Communication criteria will be returned to the authors for revision and considered as regular submissions.

Accelerated Communications should be submitted in the same format as full papers, but the Results and Discussion sections may be combined at the author’s discretion. Title, authors’ names and affiliations, footnotes, captions, legends references, and index terms should follow the forms outlined above for full papers. Manuscripts including references must not exceed 15 double-spaced typewritten pages (1 inch margins), with each figure counting as one page of typewritten text. Manuscripts exceeding these limitations will be considered as full-length papers.

F. National Auxiliary Publications Service (N.A.P.S.). In some cases, results of investigations may be of archival value, but present insufficient new information of general interest to the scientific community in terms of methodology, types of pathway, significant species differences, interrelationships with other pharmacologic or toxicologic properties, etc., to warrant publication in extended form. For deposit with the National Auxiliary Publications Service (N.A.P.S.), the data must be submitted in triplicate with the manuscript. The original copy for the documentary material will be deposited with N. A. P. S. and the accession number will be published.

Abbreviations for units of measurement should be unpunctuated, with no distinction between singular and plural forms. Multiples of units should be indicated as follows: kg, g, mg, μg (not ug, mcg, or γ), ng, pg. Abbreviations to be used for units of measurement are:

- **Mass:** g (gram); mol (mole); eq (equivalent). Do not use M as an abbreviation for mole, as M is used solely as the concentration term molar.
- **Concentration:** M (molar); N (normal); % (percent). In the latter case, the basis of formulation should be indicated as % (w/w), % (v/v), or % (w/v) to signify g/100 g, g/100 ml, or ml/100 ml. The term mg% should not be used. Mixtures should be shown as, for example: acetone/0.5 M KCl/glacial acetic acid, 1:5:2 (v/v).
- **Length:** m (meter); μm (micrometer). Where common usage dictates, Å (Ångstrom) may be used.
- **Volume:** liter should be spelled out, to avoid confusion with the numeral 1. Abbreviate compound words containing the root liter, as ml, μl, etc.

**Time:** hr (hour); min (minute); sec (second). Days and longer units of time should be spelled out.

**Radioactivity:** Ci (curie); r (roentgen); cpn or dpm (counts or disintegrations per min).

**Electricity:** V (volt); amp (amperes); Hz (cycles/sec).

**Spectrometry:** A₀₀₀ [abscissa (not OD or E) at 500 nm (not m₄) wavelength]; ε (molar absorption coefficient, with units M⁻¹ cm⁻¹); UV (ultraviolet); IR (infrared); ESR (electron-spin resonance); NMR (nuclear magnetic resonance); δ [chemical shift, with units ppm (parts per million)]; s (singlet); d (doublet); t (triplet); m (multiplet); anu (atomic mass units); m/z (mass/charge ratio).

**Chromatography:** TLC (thin-layer chromatography); Rₚ (retardation factor); GLC (gas-liquid chromatography); Rₜ (retention time); GC/MS (coupled gas chromatography-mass spectrometry); HPLC (high-pressure liquid chromatography).

**Equilibrium and kinetic constants:** Kd (dissociation constant); Kᵢ or Kᵢ (dissociation constant of enzyme-substrate or enzyme-inhibitor complex); Kₘ (Michaelis constant); Vₘₐₓ (maximum initial velocity); kᵢ (rate constant); Pₖₑₐ (negative logarithm of acidic dissociation constant); t₁/₂, half-life; AUC, area under the curve of plasma concentrations vs. time.

**Statistics:** p (probability of chance observation); N (number of experiments); SD (standard deviation of the series); SE (standard error of the mean).

**Other abbreviations:** °C (degrees of temperature); g (acceleration due to gravity, as in 9800g); rpm (revolutions per min); LD₅₀ and ED₅₀ (median lethal and effective doses); iv (intravenous); ip (intraperitoneal); im (intramuscular); sc (subcutaneous); po (peroral); m.p. (melting point); sp. (specific gravity).

**Drugs and chemicals:** The following abbreviations may be used without definition: NAD⁺, NADH, NADPH, FMN, FAD, ATP etc., RNA, DNA, UDP-glucuronic acid, Tris, EDTA; SKF 525-A; all other abbreviations should be explained in a single footnote at the point of use of the first one. Cytochromes should be named as follows: cytochrome b₅, cytochrome c, cytochrome P₄₅₀. Generic names of drugs should be used; the trade-name, capitalized, may be given in parentheses after the first use of the generic name. Where no generic name exists, a code number may be used, but the full chemical name of the compound must be given in parentheses following the first use of the name. Trade-names and code numbers should not be used in the title.

The composite character of drugs which are mixtures of stereoisomers must be brought to the attention of the reader. The prefix rac-, e.g. rac-propanolol, in the case of racemates, and (Z/E)- or cis/trans- in the case of that type of isomer is obligatory. The implications of the composite nature of the drugs studies for the interpretation of the data measured and the conclusions drawn must be made explicit.

**Page charges:** Authors are assessed page charges at the rate of $30 per printed page. With the galley proof, authors will receive a request for page charges. These charges will be assessed unless they involve personal financial hardships to the authors. Payment of the charge is not a condition for publication. Neither the editors nor reviewers know who has paid the charge.
INFORMATION FOR SUBSCRIBERS

DRUG METABOLISM AND DISPOSITION (DMD/ISSN 0090-9556) is an official publication of The American Society for Pharmacology and Experimental Therapeutics and is published by Williams & Wilkins, 351 W. Camden Street, Baltimore, MD 21201-2436. Periodicals postage paid at Baltimore, MD and at additional mailing offices. POSTMASTER: Send address changes to DRUG METABOLISM AND DISPOSITION, 351 W. Camden Street, Baltimore, MD 21201-2436.

Frequency: Monthly: One volume a year beginning in January. Printed on acid-free paper.

Correspondence concerning business matters should be addressed to: Customer Service, Subscriptions, Williams & Wilkins, 351 W. Camden Street, Baltimore, MD 21201-2436. Telephone 1-(800) 638-6423 from anywhere in the U.S. and Canada. From other countries, call (410) 528-8555. Fax: (410) 528-8596.

Correspondence regarding editorial matters should be addressed to the Editor: Dr. Raymond F. Novak, Editor, DRUG METABOLISM AND DISPOSITION, The Institute of Chemical Toxicology, Wayne State University, 2727 Second Avenue, Room 4000, Detroit, MI 48201-2654. Telephone: (313) 961-4943. Fax: (313) 961-0026 or 577-0082.

For information on Society membership, contact: American Society of Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20814. Telephone (301) 530-7060. Fax: (301) 530-7061.

Instructions to Authors appears in every issue.

Annual Subscription Rates: U.S.: Personal $90.00; Institutional $150.00; Single copy $24.00. Outside the U.S., except for Japan: Personal $115.00; Institutional $175.00; Single copy $28.00.

Institutional (multiple reader) rate applies to libraries, schools, hospitals, clinics, group practices, and federal, commercial and private institutions and organizations.

For Japanese rates, please contact: Igaku-Shoin MYW Ltd., 3-23-14 Hongo, Bunkyo-Ku, Tokyo 113, JAPAN. Telephone: (03) 5689-5400 or 5401. Fax: (03) 5689-5402.

PRICES ARE SUBJECT TO CHANGE.

The GST number for Canadian subscribers is 123394371. CPC International Publication Mail Number is 04577256. Country of origin USA.

New subscriptions received before May 1st of each year will begin with the first issue of the year. Subscriptions received between May 1st and October 31st will start with the mid-year issue (July). Subscriptions received after October 31st will start with the first issue of the following year. Subscriptions may start with any current volume’s issue upon request.

Renewals should be done promptly to avoid a break in journal delivery. The Publisher cannot guarantee to supply back issues on late renewals.

Change of address: The Publisher must be notified 60 days in advance. Journals undeliverable because of incorrect address will be destroyed. Duplicate copies may be obtained, if available, from the Publisher at the regular price of a single issue. Send address changes to DRUG METABOLISM AND DISPOSITION, 351 W. Camden Street, Baltimore, MD 21201-2436. If a member, please contact the Society with your change.

Reprints of individual articles are available only from the authors. If authors need information on their reprint orders, they can call (410) 528-4118.

Reprints (non-author) in large quantities, for commercial or academic use, may be purchased from the Publisher. For information and prices call (410) 528-4292.

Microfilm and Microfiche: Prices are available upon request. Microfilm editions may be ordered from Williams & Wilkins.

The Journal subscription list is available for rental on a controlled basis from Williams & Wilkins. All promotional literature must be approved in advance.

Disclaimer: The statements and opinions contained in the articles of DRUG METABOLISM AND DISPOSITION are solely those of the individual authors and contributors and not of the American Society for Pharmacology and Experimental Therapeutics or Williams & Wilkins. The appearance of advertisements in the Journal is not a warranty, endorsement or approval of the products or safety. The American Society for Pharmacology and Experimental Therapeutics and the Publisher disclaim responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.

Volume indices appear in the December issue.

Indexing/Abstracting Services: The Journal is currently included by the following services in print and/or electronic format: Index Medicus, Current Contents (Life Sciences), Excerpta Medica, Biosciences Information Service, and Reference Update/Research Information Systems.

Copyright Information: DRUG METABOLISM AND DISPOSITION is copyrighted by the American Society for Pharmacology and Experimental Therapeutics. No portion(s) of the work(s) may be reproduced without written consent from Williams & Wilkins. Permission to reproduce copies of articles for noncommercial use may be obtained from the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923, (508) 750-8400 with a fee of $3.00 per copy.

Copyright © 1996 by the American Society of Pharmacology and Experimental Therapeutics.
Broad coverage of pharmacology in a prestigious journal

THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Editor: John Harvey, PhD,
The Medical College of Pennsylvania

☐ Yes! Please start my subscription.
Avoid future rate increases and ensure uninterrupted service—enter your multiyear subscription today!

The Journal of Pharmacology and Experimental Therapeutics (monthly)
☐ Individual $190/ year
☐ Institutional $370/ year
(Add $75/year for postage outside the U.S.; in Canada, also add 7% GST)

☐ New Subscription ☐ Renewal
☐ 3 years ☐ 2 years ☐ 1 year

PAYMENT OPTIONS:
☐ Check enclosed (payable to Williams & Wilkins)
☐ Bill me ☐ Am Ex ☐ MC ☐ VISA

Card # Exp. date

Signature/P.O.#

Name

Address

City / State / Zip / Country

MD, ME, and L subscribers must add state sales tax. Subscriptions outside the U.S. must be prepaid in U.S. dollars only. In Japan, contact Yokohama Shoin MW, Ltd. (03) 5689-5459. Rates valid through October 31, 1998.

Discounts available to members on all ASPET publications. SAVE 10% when ordering two. SAVE 15% when ordering three. SAVE 20% when ordering all four.

Return coupon to: Williams & Wilkins, A Waverly Company, P.O. Box 20391, Baltimore, MD 21205-0390.

PT 5649
Printed in USA 564044Z

JPET is respected worldwide as one of the leading research journals in the field of pharmacology. Readers find broad coverage of all aspects of the interactions of chemicals with biological systems, including:

- autonomic pharmacology
- analgesia
- behavioral pharmacology
- cardiovascular pharmacology
- cellular pharmacology
- chemotherapy
- clinical pharmacology
- developmental pharmacology
- drug abuse
- drug metabolism & disposition
- gastrointestinal pharmacology
- immunopharmacology
- neuropharmacology
- pulmonary pharmacology
- renal pharmacology
- toxicology

JPET is valuable reading for academic, industrial and clinical pharmacologists as well as toxicologists. The Journal deserves a place in every pharmaceutical and toxicological research laboratory and pharmacology/toxicology department throughout the world. Monthly

To order by credit card, call TOLL-FREE 1-800-638-6423 in North America. Outside North America, fax: +410-361-8048 or call one of our international offices: Tokyo (03) 5689-5400, London 0171-385-2257, Hong Kong 852-2610-2339.
1996 Gordon Research Conference on
Drug Metabolism

July 7-12
Holderness School • Plymouth, New Hampshire

Sessions Include:

Keynote Lecture

Anthony Y. H. Lu (Merck; Rahway, NJ)

Pharmacogenetics and Cancer Chemotherapy

Discussion Leader: William E. Evans (St. Jude's; Memphis, TN); Speakers: David Waxman (Boston U.; Boston, MA) “P450 activation of oxazaphosphorine anticancer drugs: development of a combined chemotherapy/gene therapy strategy.” Frank Gonzalez (NCI; Bethesda, MD) “Genetic polymorphism of dihydropyrimidine dehydrogenase and 5-fluorouracil therapy: molecular mechanisms and clinical consequences.” William Evans (St. Jude's; Memphis, TN) “Genetic polymorphism of thiopurine S-methyltransferase and thiopurine therapy: molecular mechanisms and clinical consequences.”

Pharmacogenetics of the Glutathione S-transferases


Drug Metabolism in the Brain

Discussion Leader: Henry Strobel (UT Med. School; Houston, TX); Speakers: Jean-Francois Gherzi-Egea (Institut Pasteur; Lille, France) “Roles of blood-brain barrier in cerebral drug metabolism.” Hidenori Kawashima (UT Med. School; Houston, TX) “Brain cytochromes P-450 and mental diseases.” Arthur Cooper (Cornell Univ.; NY) “Cysteine conjugate β-lyases.”

Drug Metabolism as a Determinant of Drug Toxicity


Phase III Metabolism: The Export of Drugs and Metabolites

Discussion Leader: Terrence J. Monks (U. Texas; Austin, TX); Speakers: Piet Borst (Nederlands Kanker Inst. Amsterdam; The Netherlands) “The GS-X pump.” Jeff Silverman (NCI; Bethesda, MD) “Xenobiotic regulation of the rat multi-drug resistance lb gene.” Mary Vore (U. Kentucky; Lexington, KY) “Does canalicular P-glycoprotein mediate estrogen glucuronide cholestasis?”

Drug Metabolism Data Blitz

Discussion Leader: Serrine S. Lau (U. Texas; Austin, TX); Selected presentations from conferees.

Drug Metabolism in Drug Discovery and Drug Development

Discussion Leader: Brian Smith (SmithKline Beecham; King of Prussia, PA); Speakers: Brian Smith (SmithKline Beecham; King of Prussia, PA) “Strategies to facilitate the discovery to development transition.” Andrew Ayton (SmithKline Beecham; King of Prussia, PA) “In vitro biotransformation in the drug discovery process.” Martin Dyroff (Zeneca; Wilmington, DE) “The role of drug metabolism and pharmacokinetics during drug hunting and optimization.”

Technological Advances in Drug Metabolism


For further information please contact Dr. Terrence J. Monks, Univ. Texas @ Austin. FAX (512) 471-5002 • Email, scouser@mail.utexas.edu